Additional file 1: Figure S1. Roquin1 expression is reduced in several human cancers, and positively associated with patient survival. a Comparison of Roquin1 mRNA expression between normal (0) (n = 7) and ductal breast carcinoma (1) (n = 40). b Comparison of Roquin1 mRNA expression among normal (0) (n = 65), large cell lung carcinoma (1) (n = 19), lung adenocarcinoma (2) (n = 45), and squamous cell lung carcinoma (3) (n = 27). c Comparison of Roquin1 mRNA expression among normal (0) (n = 5), ovarian clear cell large cell adenocarcinoma (1) (n = 7), ovarian endometrioid adenocarcinoma (2) (n = 9), ovarian mucinous adenocarcinoma (3) (n = 9), and ovarian serous adenocarcinoma (4) (n = 20). d Comparison of Roquin1 mRNA expression in normal (0) (n = 31), diffuse gastric adenocarcinoma (1) (n = 6), and gastric adenocarcinoma (2) (n = 2). e Comparison of Roquin1 mRNA expression in normal (0) (n = 3), bladder cancer (1) (n = 3), bladder squamous cell carcinoma (2) (n = 1), bladder urothelial carcinoma (3) (n = 3), infiltrating bladder urothelial carcinoma (4) (n = 34), bladder papillary urothelial carcinoma (5) (n = 1), and superficial bladder cancer (6) (n = 17). f-j Kaplan-Meier overall survival curve of patients with lung cancer (f), ovarian cancer (g), gastric cancer (h), bladder carcinoma (i), and liver cancer (j) having low and high tumor Roquin1 transcripts. Figure S2. Roquin1 inhibits cell proliferation and induces G1/S phase cell cycle arrest in tumor cells. a-b Cell counting was carried out every 24 h in A549 (a) and HepG2 (b) cells with Roquin1/GFP overexpression. ***P